Candel Therapeutics, Inc. (CADL): Rasio rega marang prakiraan pendapatan
Risks for Candel Therapeutics (CADL) are limited solely to formal compliance with environmental regulations and reagent disposal. The issuer's forward P/S visualizes these aspects, where the 1523.70 mark indicates the current state. Stability is ensured by the patent protection of viral platforms and regulatory complexity. Growth potential is based on inelastic demand for unique metastasis destruction methods, which guarantees high pricing power for Candel Therapeutics (CADL).
candeltx.com (CADL) - rincian metrik lan laporan keuangan
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Candel Therapeutics|CADL - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Candel Therapeutics, Inc.|CADL - Kewajiban utang agregat|Utang marang nilai buku Candel Therapeutics, Inc.|CADL - Gedhene kewajiban jangka dawa|Utang jangka cendhak perusahaan Candel Therapeutics|Rasio cepet candeltx.com
- rincian asil keuangan lan kelipatan valuasi:
CADL - Penghasilan resik perusahaan|Bathi sing dikarepake Candel Therapeutics|CADL - Nilai perusahaan marang bathi resik|Pangali Forward P/E Candel Therapeutics, Inc.|CADL - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Candel Therapeutics, Inc.|CADL - Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi|Bathi resik saben saham (EPS TTM) Candel Therapeutics|CADL - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan candeltx.com|CADL - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Candel Therapeutics
- indikator dodolan lan pendapatan:
Ringkesan analisis perusahaan:Candel (CADL)
Screening market value relative to projected revenue is critical for constructing a defensive portfolio within the biopharmaceutical sector. This metric correlates the capitalization of Candel Therapeutics (CADL) with expected sales, determining the degree of asset overvaluation within a drug development cycle that remains independent of macroeconomic trends. Analyzing the expected P/S chart for Candel Therapeutics (CADL) allows for an assessment of whether current quotes are fair relative to the business's fundamental prospects.
Perusahaan pesaing
Multiplikator Forward P/S ONC (BeiGene)|Multiplikator Forward P/S Halozyme Therapeutics, Inc. HALO|RVMD - Rasio rega marang prakiraan pendapatan|AAPG (Ascentage Pharma Corp) - Kapitalisasi marang prakiraan pendapatan|CGON: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan URGN|BCAX (Bicara Therapeutics) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Personalis Inc PSNL|Rasio rega marang prakiraan pendapatan Erasca Corp (ERAS)|Rasio rega marang prakiraan pendapatan DCTH (Delcath Corp)|Y-mAbs Therapeutics - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan AURA|ARAY: Multiplikator forward rega marang pendapatan|SELLAS Life Sciences - Rasio rega marang pendapatan sing dikarepake|ACTU: Multiplikator Forward P/S|Citius Oncology Inc - Rega forward marang dodolan|HURA (TuHURA Biosciences Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep protaratx.com TARA|Rasio rega marang prakiraan pendapatan Fate Therapeutics (FATE)|WHWK (aadibio.com) - Rega forward marang dodolan|Multiplikator Forward P/S TCRX (TScan Therapeutics, Inc.)|Multiplikator Forward P/S Champions Oncology Inc CSBR|XBIT - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan CVM|OSTX: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep radiopharmtheranostics.com (RADX)|Multiplikator forward rega marang pendapatan ARTV|Multiplikator Forward P/S Adlai Nortye Limited|Multiplikator forward rega marang pendapatan VERU (Veru Inc.)|Rasio rega marang pendapatan sing dikarepake TPST|Multiplikator Forward P/S XLO (Xilio Therapeutics)|Rasio kapitalisasi marang dodolan sing dikarepake Renovaro Biosciences (RENB)|Mural Bio - Multiplikator Forward P/S|Kairos Pharma Ltd (KAPA) - Multiplikator forward rega marang pendapatan|onkuretherapeutics.com (OKUR) - Rasio rega marang prakiraan pendapatan|GDTC - Rasio kapitalisasi marang dodolan sing dikarepake|CRIS (Curis Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Apollomics Corp (APLM)|Multiplikator Forward P/S THAR|Multiplikator Forward P/S advanbiomed.com (ADVB)|Multiplikator Forward P/S GNPX (Genprex, Inc.)|CLDI: Kapitalisasi marang prakiraan pendapatan|SBFM - Rasio rega marang prakiraan pendapatan|XBIO: Rasio rega marang prakiraan pendapatan|SLRX: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Kitov Pharma|AONC (American Oncology Network Inc) - Multiplikator Forward P/S|Multiplikator Forward P/S beigene.com|Rasio rega marang prakiraan pendapatan Checkpoint Therapeutics, Inc. (CKPT)|elevationoncology.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S ICAD (iCAD)|IKNA - Multiplikator forward rega marang pendapatan|Notable Labs, Ltd. - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Viracta Therapeutics|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|NAYA Biosciences Inc - Rega forward marang dodolan|Multiplikator forward rega marang pendapatan AAPGV
